DGAP-News

4SC AG: 4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China - Seite 2

this cancer drug and look forward to a productive and value-adding
partnership."

- End of press release -

Further information

About 4SC-205

4SC-205 is a cancer compound that inhibits the so-called "kinesin spindle
protein" Eg5, which plays a key role in cell division and therefore the
growth of cancer cells. Cell division inhibitors are deployed with great
success in oncology, although they have serious side effects. Due to
4SC-205's special mode of action, the compound does not cause such side
effects. To the best of the Company's knowledge, 4SC-205 is the only Eg5
inhibitor available as a tablet that is currently in clinical development.
In a Phase I study, the substance has already shown to be safe and well-
tolerated in different dosing schemes. Additionally, initial indications of
efficacy were determined.

About 4SC

4SC (www.4cs.com) is a biotechnology company dedicated to the research and
development of small-molecule drugs focused on epigenetic mechanisms of
action for the treatment of cancers with high unmet medical needs. These
drugs are intended to provide innovative treatment options for cancer
patients that are more tolerable and efficacious than existing therapies,
provide a better quality of life and offer increased life expectancy. The
Company's pipeline comprises promising products that are in various stages
of clinical development. 4SC's aim is to generate future growth and enhance
its enterprise value by entering into partnerships with pharmaceutical and
biotech companies. Founded in 1997, 4SC had 50 employees at 1 May 2016. 4SC
has been listed on the Prime Standard of the Frankfurt Stock Exchange since
December 2005.

About Link Health

Link Health is a high-quality pharmaceutical company focused on licensing,
registration, clinical study and regulatory consulting services in the
Greater China area. Link Health aims at unveiling and promoting innovative
drugs, which are made to address crucial medical needs. Based on several
years' experience in the pharmaceutical industry, Link Health created a
strong team to provide solutions for regulatory, (pre)clinical research,
licensing, partnering and communications (IND, NDA applications) with the
CFDA (China Food and Drug Administration), among others. Link Health has
expertise in the licensing and co-development of INDs and devices at
clinical stage.

Operating from the Chinese market, Link Health specializes in linking
businesses from different markets to the mutual benefit of each other. The
professional teams target and screen the best innovations in medical